New facility will provide lyophilization services
Oregon Freeze Dry (OFD), a lyophilization and freeze-drying company, has opened a new biopharmaceutical development and clinical facility in Albany, OR. The $7.5 million facility is designed to support the development of traditional pharmaceutical active ingredients, combination products, and medical devices, as well as support lyophilization process development.
The Albany facility will also host lyophilization process development and clinical trials, and features environmental controls that can support development of oral drugs. The center is OFD’s fifth facility in the US, and is anticipated to add at least six new positions to a staff of more than 450.
“Our new facility supports the vision of a world where vaccines and medications can bypass a syringe and be administered orally, increasing access to life-changing medicine around the world,” says Joe Folds, OFD’s president and CEO. “We’re ready and eager to collaborate with pharmaceutical companies and support advances in microbial therapeutics, immunotherapy, and cell and gene therapy.”
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.